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Abstract
Background: Comorbidity of psychiatric and substance use disorders represents a significant complication in the
clinical course of both disorders. Bipolar Disorder (BD) is a psychiatric disorder characterized by severe mood
swings, ranging from mania to depression, and up to a 70% rate of comorbid Tobacco Use Disorder (TUD). We
found epidemiological evidence consistent with a common underlying etiology for BD and TUD, as well as
evidence of both genetic and environmental influences on BD and TUD. Therefore, we hypothesized a common
underlying genetic etiology, interacting with nicotine exposure, influencing susceptibility to both BD and TUD.
Methods: Using meta-analysis, we compared TUD rates for BD patients and the general population. We identified
candidate genes showing statistically significant, replicated, evidence of association with both BD and TUD. We
assessed commonality among these candidate genes and hypothesized broader, multi-gene network influences on
the comorbidity. Using Fisher Exact tests we tested our hypothesized genetic networks for association with the
comorbidity, then compared the inferences drawn with those derived from the commonality assessment. Finally,
we prioritized candidate SNPs for validation.
Results: We estimate risk for TUD among BD patients at 2.4 times that of the general population. We found three
candidate genes associated with both BD and TUD (COMT, SLC6A3, and SLC6A4) and commonality analysis
suggests that these genes interact in predisposing psychiatric and substance use disorders. We identified a 69
gene network that influences neurotransmitter signaling and shows significant over-representation of genes
associated with BD and TUD, as well as genes differentially expressed with exposure to tobacco smoke. Twenty
four of these genes are known drug targets.
Conclusions: This work highlights novel bioinformatics resources and demonstrates the effectiveness of using an
integrated bioinformatics approach to improve our understanding of complex disease etiology. We illustrate the
development and testing of hypotheses for a comorbidity predisposed by both genetic and environmental
influences. Consistent with our hypothesis, the selected network models multiple interacting genetic influences on
comorbid BD with TUD, as well as the environmental influence of nicotine. This network nominates candidate
genes for validation and drug testing, and we offer a panel of SNPs prioritized for follow-up.
Background
Bipolar Disorder (BD) is a severe psychiatric disorder,
characterized by periods of mania and depression, which
affects approximately 1% of the U.S. population, or 3 -
5% if BD spectrum disorders (BPII and BP-NOS) are
included [1,2]. Tobacco Use Disorder (TUD) is the
single greatest cause of preventable death in the United
States [3,4] and it disproportionately affects psychiatric
patients [5]. Note that TUD is defined as “Tobacco used
to the detriment of a person’s health or social function-
ing. Tobacco dependence is included.”, according to the
Medical Subject Heading (MeSH) index [6]. In earlier
work, various research groups used “nicotine depen-
dence”, “nicotine addiction”, “tobacco dependence”, or* Correspondence: mceachin@umich.edu
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“smoking” to characterize the phenotype, but there is no
clear standard term in the literature. We use the MeSH
term, TUD, in these analyses because it incorporates the
information derived from these multiple sources and
facilitates the bioinformatics analyses. There is evidence
of increased risk for TUD among BD patients [1,7-12]
as well as evidence that smokers may be at increased
risk for BD [1,9]. While it is possible that TUD could
predispose individuals to BD, or BD could predispose
individuals to TUD, the observed bi-directional
increased risk for both disorders is consistent with some
common underlying etiology for BD and TUD.
There is epidemiological evidence of multiple genetic
influences on both BD [13] and TUD [14]. In family and
twin studies, heritability of BD is estimated at 75 to 85%
[15,16], consistent with one or more genetic influences
on BD susceptibility. Still, even for monozygotic twins,
concordance is estimated at only about 67% [17], consis-
tent with environmental influences on BD susceptibility.
Heritability of TUD is estimated at 37 to 56% for initia-
tion of smoking, and 59 to 70% for transition to nicotine
dependence [18,19], consistent with one or more genetic
influences on TUD susceptibility. In addition, nicotine
binds to cell surface nicotinic acetylcholine receptors,
and so represents an environmental effect which would
be expected to influence intracellular signal transduction
pathways. Given the potential for some common under-
lying etiology for BD and TUD, as well as evidence of
genetic and environmental influences on both BD and
TUD, we hypothesized a common underlying genetic
etiology, interacting with environmental nicotine expo-
sure, influencing susceptibility for both BD and TUD.
Figure 1 outlines the overall analysis flow. After asses-
sing the strength of evidence for comorbidity of BD and
TUD via meta-analysis, and seeing an increased Relative
Risk consistent with some common etiology, we identi-
fied candidate genes for the comorbidity. The analysis
then followed two parallel paths. First, in complex dis-
eases multiple genetic influences converge on a single
phenotype (in this case, co-morbid BD with TUD). We
presume that to influence a single phenotype these mul-
tiple genetic influences must impact some common ele-
ment(s) associated with the phenotype (e.g., a common
pathway, tissue, cellular function, disease or other pro-
cess). We exploited this convergence on a single pheno-
type by identifying significant commonality among the
selected candidate genes. We then used this commonal-
ity to improve our understanding of the roles of these
genes in both BD and TUD. In a parallel analysis, we
generated networks of genes that interact with our
selected candidate genes. Based on these interactions,
we hypothesized models of the larger set of genetic
influences on co-morbid BD with TUD, then tested
each of these hypotheses for enrichment of BD and
TUD associated genes. As with the commonality analy-
sis, analysis of gene networks enriched for BD and TUD
associated genes may improve our understanding of the
comorbidity, so we compared lessons learned in the
commonality and network analyses. Finally, while no
GWA studies have yet been conducted specifically to
identify candidate genes for this co-morbidity, we priori-
tized Single Nucleotide Polymorphisms (SNPs) for fol-
low-on studies by functional data, as well as by
combining evidence from two GWA studies (one for BD
and one for TUD).
Methods
Meta-analysis (Figure 1a)
We first assessed the strength of evidence for comorbid-
ity of BD and TUD, based on the published literature.
Querying all of PubMed, we found seven studies pub-
lished on the subject between 1986 and 2008 [1,7-12].
From each study, we selected the data specific to
comorbid BD with TUD and ensured that the pheno-
types studied were consistent, then generated a com-
bined spreadsheet of the raw data (Additional file 1,
Forest Notes). Using MIX Meta-Analysis software
[20,21] (version 1.7), we generated an annotated forest
plot of Relative Risk, using first a fixed effects model
Figure 1 analysis flow. Analysis proceeds from meta-analysis, to
hypothesis generation, to candidate gene selection, common
elements assessment, network hypothesis generation, hypothesis
testing, comparison of results, and SNP prioritization.
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with Mantel-Haenszel weighting then a random effects
model with DerSimonian-Laird weighting. All other
MIX parameters were set at the default values, under
the Analysis/preferences tab. For details of the meta-
analysis see Additional file 2, MOOSE Checklist [22].
Candidate gene selection (Figure 1b)
We used Gene2MeSH [23], a novel bioinformatics
resource from the National Center for Integrative Bio-
medical Informatics (NCIBI), to select candidate genes
for comorbid BD with TUD on 8 April, 2009. Gene2-
MeSH identifies genes and MeSH terms that co-occur
in PubMed-indexed manuscripts that are annotated for
both the genes referenced and the MeSH terms
assigned. Gene2MeSH allows the user to input a MeSH
term and find all genes significantly over-represented in
publications annotated for that term. In this mode, Gen-
e2MeSH requires MeSH terms as input and we used the
MeSH database [6] to identify appropriate MeSH terms
to query Gene2MeSH for genes related to BD and TUD.
MeSH has only one term for BD, “bipolar disorder”,
which we used in the Gene2MeSH query to identify a
preliminary set of human BD candidate genes. In addi-
tion to TUD, MeSH has two related terms so we quer-
ied “tobacco use disorder”, “nicotine” and “smoking”,
then used the union of these three human gene sets as a
preliminary set of TUD candidate genes.
Gene2Mesh generates a Fisher Exact p-value to quan-
tify the over-representation of genes occurring in publi-
cations annotated for a given MeSH term, relative to all
papers in PubMed, and select genes based on a thresh-
old of Fisher Exact p-value ≤ 10-4. However, co-occur-
rence of genes with MeSH terms is not the same as
association. We tested each preliminary candidate gene
for evidence of association between the gene and the
appropriate phenotype (i.e., BD or TUD) by reading the
papers cited by Gene2MeSH. We accepted in our final
“overlapping” set only those preliminary candidate genes
for which we found at least two studies that showed sta-
tistically significant positive association (Bonferroni cor-
rected p-value ≤ 0.05) with both BD and TUD, in the
peer reviewed literature. We did not consider power, as
this parameter is generally not reported in the literature.
Common elements (Figure 1c)
In complex diseases, multiple genetic influences con-
verge on a single phenotype, consistent with some com-
mon element(s) among these genetic influences (e.g., a
common disease process, metabolic or signaling path-
way, cellular component, or tissue expression). Under-
standing commonality among our candidate genes may
yield useful inference on how multiple genetic influences
converge on the co-morbidity. We assessed two
resources available for commonality testing: PDG-ACE
(Prioritizing Disease Genes by Analysis of Common Ele-
ments) [24,25] from NCIBI, and GRAIL (Gene
Relationships Across Implicated Loci) [26] from the
Broad Institute. Both PDG-ACE and GRAIL generate
hypotheses on gene-gene interactions and also provide
quantitative measures of the strength of evidence in
support of each hypothesis.
PDG-ACE identifies significant commonality across
genetic loci based on text in the Entrez Gene records of
genes at locus pairs. We submitted our set of three
overlapping candidates to PDG-ACE in pairs, performed
107 iterations for significance testing using PDG-ACE’s
MeSH-derived controlled vocabulary of 2,531 keywords,
applied a Bonferroni correction for these 2,531 hypoth-
esis tests, and stored the keywords that were signifi-
cantly over-represented (corrected p-value ≤ 0.05) at
each locus pair. For these stored keywords, we assessed
the context of each keyword in the Entrez Gene records
for each locus and retained those keywords that were
used in the same context at both loci. Since the Entrez
Gene records for these genes include links to the
PubMed abstracts, we followed each of these links to
identify trends that may be useful in understanding the
roles of these genes in co-morbid BD with TUD.
GRAIL also finds commonality among genes, though,
with GRAIL commonality is based on PubMed abstracts.
On 8 July, 2009, we input our overlapping candidates to
the GRAIL server and set the query regions to equal the
seed regions, as recommended in the GRAIL FAQs
when the number of input genes is small. We compared
the returned keywords associating the overlapping can-
didate genes to our PDG-ACE results and assessed their
context with respect to comorbid BD with TUD.
Hypothesis generation: network model building (Figure
1d)
We assessed three resources for building models of
genetic interactions among our candidate genes: MiMI
(Michigan Molecular Interactions) from NCIBI [27],
STRING (Search Tool for the Retrieval of Interacting
Genes/Proteins) from the European Molecular Biology
Lab [28,29], and MetaCore [30] from GeneGo Inc. Each
of the models developed using these resources repre-
sents one hypothesis on how multiple genetic variants
could interact to influence the comorbidity. To focus on
the interactions most closely tied to the overlapping
candidate genes (and, we assume, most likely to influ-
ence comorbid BD with TUD), we set input parameters
to accept only the highest quality interactions data and
to build the smallest network that includes all of the
overlapping candidate genes in a single model.
MiMI includes comprehensive protein interaction
information that has been integrated and merged from
diverse protein interaction databases. For input of multi-
ple genes, MiMI is implemented as a plug-in for Cytos-
cape [31] (version 2.6.0), an open source bioinformatics
platform for visualizing molecular interaction networks.
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MiMI does not have a parameter for selecting the level
of confidence for interactions. We input our list of three
overlapping candidate genes and selected the “Interac-
tions among query genes” option. This network did not
include all three of the overlapping candidates in a sin-
gle network so we moved to the “Query Genes + Near-
est Neighbors” option and this produced a single
network including all three overlapping candidates. We
downloaded the network in both graphical and text
formats.
STRING is a database of known and predicted protein
interactions including: direct (physical) and indirect
(functional) associations derived from genomic context,
high-throughput experiments, conserved co-expression,
and publications. We input our list of overlapping can-
didate genes, set the minimum combined score to 0.900
(highest confidence) and built the network. The result-
ing network did not connect the three overlapping can-
didate genes, so we had STRING add nodes to the
network, one at a time, until all of the overlapping can-
didate genes were included in a single network. We
downloaded the network in both graphical and text
formats.
MetaCore (GeneGo Inc.) is a commercial database of
human curated data on gene-gene, gene-DNA, and
gene-small molecule interactions. The types of interac-
tions data available are equivalent to those available in
STRING. Starting with our three overlapping candidates,
we set parameters for the “Shortest Paths” network
building algorithm and “curated only” data, accepting
unspecified effects as well as functional and binding
interactions (MetaCore version 6.0). We first looked for
direct interactions, then increased the number of nodes
allowed between the overlapping candidate genes until
they were all included in a single network. The resulting
network is comparable to the MiMI and STRING
networks.
An important feature of GeneGo, not yet available in
MiMI or STRING, is that it allows the user to add
selected nodes (genes, small molecules, etc.) to an estab-
lished network. To help assess the environmental impact
of nicotine on the hypothesized network for comorbid
BD with TUD, we added nicotine to the network. Gen-
eGo has a built in test for over-representation of genes
in documented pathways, so we tested the network for
pathway association. We downloaded both GeneGo net-
works, one excluding nicotine and one including nico-
tine, in both graphical and text formats.
Hypothesis testing (Figure 1e)
For each of our hypothesized networks, we first used the
Genetic Association Database (GAD) [32] via the
DAVID interface (Database for Annotation, Visualiza-
tion and Integrated Discovery) [33,34], to test for over-
representation of genes associated with BD and TUD. In
addition, since nicotine represents an environmental
influence on our hypothesized networks and differential
gene expression is one of the most important ways that
cells respond to the environment, we used NCIBI’s Con-
ceptGen [35] software application to test for differential
gene expression related to BD and/or TUD.
GAD is an archive of results from human genetic asso-
ciation studies of complex diseases and disorders, which
has been made available for assessment of gene sets via
DAVID. If, based on GAD data, a given network is over-
represented for genes associated with both BD and TUD,
the network may lead us to a clearer understanding of
how the multiple genetic influences converge on the
comorbidity. GAD provides dichotomous annotation of
genes, based on published evidence, where each gene
either has shown evidence or has not (yet) shown evidence
of association with a specific phenotype (e.g. BD or TUD).
DAVID uses this dichotomous annotation in a modified
Fisher Exact test, where the count of positive agreement is
reduced by 1 to make a more conservative test, to assess
gene sets for over-representation of genes annotated for
specific phenotypes. For each of the gene sets nominated
by our network building tools (MiMI, STRING, and two
GeneGo networks), we set DAVID to assess GENETI-
C_ASSOCIATION_DB_DISEASE functional annotation.
The resulting tables provide test data including the False
Discovery Rates (FDR) for specific disease phenotypes. We
set FDR ≤ 5% as the threshold for over-representation of
genes for any GAD phenotype. Each network, as a whole,
may be over-represented for genes associated with BD
and/or TUD. However, each of these networks includes
the three overlapping candidates, which are already docu-
mented to be associated with both BD and TUD. As such,
we tested each network a second time, excluding the over-
lapping candidates. The first test for each network serves
as a positive control, where we expect to find evidence in
GAD supporting association with BD and TUD. The sec-
ond test, excluding the overlapping candidates, tests
whether the network provides significant new information
on association with BD and/or TUD, beyond the influence
of the overlapping candidates.
In a second phase of hypothesis testing, we used Con-
ceptGen [35] to test the genes in the larger GeneGo
network for over-representation of genes differentially
expressed with nicotine exposure. ConceptGen uses a
custom-built analysis pipeline for processing Affymetrix
GEO [36] datasets from raw data, testing for differen-
tially expressed genes [37], then building concepts to
represent the expression profiles. ConceptGen assesses
over-representation of gene groups for given concepts
by enrichment testing, using the same modified Fisher
Exact test as in DAVID. After seeing significant over-
representation of genes associated with BD and TUD in
the GeneGo network that includes nicotine, we queried
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ConceptGen for “Gene Expression” concepts that show
over-representation of the genes in this network. As in
our GAD analysis, we set a threshold of FDR ≤ 0.05 for
over-representation of any differentially expressed gene
set. (Note that ConceptGen presents FDR as a decimal
value while GAD presents FDR as a percentage.)
Inference from common elements versus network model
building (Figure 1f)
The common elements analysis is based on only the
overlapping candidate genes, while the network model
building analysis includes additional candidate genes.
Since these results are related, we compared the infer-
ence that could be drawn from the two approaches.
Prioritizing candidate SNPs for follow-on testing via GIN
(Figure 1g)
We first prioritized SNPs in and near the genes in our
selected network via the Genomic Information Network
(GIN) method developed by Saccone et al. [38]. GIN
prioritizes SNPs based on biological relevance, as deter-
mined by SNP/gene functional properties including
synonymy, annotation for promoter regions, and
human/mouse evolutionary conservation. Second, while
there are not yet any published GWAS results for co-
morbid BD with TUD, we further prioritized SNPs by
weighting them based on evidence from the NicSNP
GWA [39,40] study of nicotine dependence and the
GAIN GWA study of BD[41].
Results
Meta-analysis
Based on our fixed effects model, we estimated Rela-
tive Risk for TUD among BD patients at 2.77, with a
p-value < 0.01, and a 95% confidence interval of 2.62
to 2.92. Based on the random effects model, we esti-
mated Relative Risk for TUD among BD patients at
2.39, with a p-value < 0.0001, and 95% confidence
interval of 1.88 to 3.03 (Figure 2). In the random
effects model, Tau2, an estimate of between-study var-
iance, is small and the Q-index, a measure of lack of
credibility among the studies, is zero (Additional file 3,
Table S1). Since the Relative Risk estimates are consis-
tent across the two models, we proceed with the more
conservative estimate of 2.39.
Overlapping candidate genes
Gene2MeSH-nominated candidates for comorbid BD with
TUD include: catechol-O-methyltransferase (COMT,
Entrez GeneID 1312); solute carrier family 6 (neurotrans-
mitter transporter, dopamine), member 3 (SLC6A3, Gen-
eID 6531); solute carrier family 6 (neurotransmitter
transporter, serotonin), member 4 (SLC6A4, GeneID
6532); tryptophan hydroxylase 1 (TPH1, GeneID 7166);
and dopamine receptor D4 (DRD4, GeneID 1815). Vali-
dating these preliminary candidate genes by searching for
at least two studies showing statistically significant positive
association (Bonferroni corrected p-value ≤ 0.05) with
both BD and TUD, we found that only COMT [42-47],
SLC6A3 [48-57], and SLC6A4 [58-63] meet the require-
ment. TPH1 had one documented significant association
with BD and one significant association with TUD, while
DRD4 had four significant associations with TUD but only
one significant association with BD.
Common elements
For all three locus pairs formed by our overlapping can-
didate genes, PDG-ACE reports “monoamine,
Figure 2 Annotated forrest plot of relative risk for TUD among BD patients. Study authors, dates, counts of smokers with BD, and counts
of smokers among controls are shown on the left. On the right, the MIX software weights each study then calculates Relative Risk and 95%
confidence intervals for TUD among BD patients. A graphical representation of this data is seen in the middle. The META-ANALYSIS study
summarizes the weighted contributions of each individual study and shows a Relative Risk of 2.39 for TUD among BD patients, with a 95%
confidence interval of 1.88 to 3.02.
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psychiatric, and attention” as significantly over-repre-
sented keywords (Figure 3). For the COMT/SLC6A4
pair, “lithium, suicide, prefrontal cortex, illness, trait,
and behavioral” were significantly over-represented. For
the COMT/SLC6A3 pair, “norepinephrine and focused”
were significantly over-represented. For SLC6A3/
SLC6A4, “methamphetamine and cocaine” were signifi-
cantly over-represented. In assessing the context of
these keywords in the Entrez Gene records of each
locus, we noted that the keywords are consistent with
psychiatric disorders, substance use disorders, and atten-
tion deficit hyperactivity disorder. In addition, the publi-
cations describing these effects indicate that these genes
show gender specific effects with respect to both psy-
chiatric disorders and substance use disorders [57,64-78]
GRAIL reported: “transporter, dopamine, serotonin,
polymorphism, methyltransferase, genotype, allele, asso-
ciation, schizophrenia, disorder, dopaminergic, psychia-
tric, subjects, polymorphisms, uptake, attention, patients,
anxiety, risk, and depression” as the keywords describing
commonality among the overlapping candidate genes.
As in the PDG-ACE analysis, we made note of the con-
text of these keywords including: psychiatric disorders,
neurotransmitter signaling, genetic variation, and atten-
tion. GRAIL quantifies similarity among loci (Table 1)
and provides a single p-value to characterize the associa-
tion. Note that ARVCF (Armadillo Repeat gene deletes
in Velocardiofacial syndrome, GeneID 421) is adjacent
to COMT on chromosome 22, so it is included in the
GRAIL gene set.
MiMI network
The smallest network hypothesized by MiMI that con-
tains all of the overlapping candidate genes has 41 genes
total (Figure 4). We organized the graphic in three
blocks, each anchored by one of the overlapping candi-
date genes. Table 2 displays the genes in the MiMI net-
work. The MiMI database focuses primarily on protein-
protein binding interactions, so edges in this network
represent binding reactions between proteins coded by
genes in the network. The genes in this network became
input to the GAD analysis.
STRING network
The smallest network hypothesized by STRING, con-
taining all of the overlapping candidate genes at the
highest level of confidence is shown in Figure 5. To
connect our overlapping candidates to each other,
STRING added four nodes to the network. Genes in the
resulting network include the overlapping candidates
(COMT, SLC6A3, and SLC6A4) as well as SNCA
[(synuclein, alpha (non A4 component of amyloid pre-
cursor), GeneID 6622), labeled as NACP in Figure 5];
DRD2 (dopamine receptor D2, GeneID 1813); MAOA
(monoamine oxidase A, GeneID 4128); and MAOB
(monoamine oxidase B, GeneID 4129). STRING reports
multiple types of interactions and Table 3 reports the
various association scores among the gene pairs. Note
that we have omitted columns of zero scores from
Table 3, though STRING also reports neighborhood
score, fusion score, co-occurrence score, homology
score, and co-expression score. STRING adds nodes
based on decreasing “combined score”, so DRD2 was
the last node added, interacting with COMT, SLC6A3,
and SLC6A4. The genes in this network became input
to the GAD analysis.
GeneGo networks
The smallest network hypothesized by GeneGo containing
all three of the overlapping candidate genes required add-
ing up to 4 nodes between each of the overlapping candi-
dates, yielding a maximum path length of 5 edges, in a
network containing 52 genes (Additional file 4: Figure S1).
As with the MiMI and STRING networks, the genes in
this network became input to the GAD analysis. This net-
work, modified to include the 17 nodes that connect nico-
tine to the network (via p53, lower right, and BDNF, top
right) is shown in Figure 6. The resulting network contains
69 genes, listed in Table 4, and the graphic is organized to
illustrate the feedback loop formed by this network.
Figure 3 PDG-ACE results . Keywords are significantly over-
represented in the Entrez Gene text at gene pairs (on the edges) or
at all three genes (in the middle). These keywords pose hypotheses
on the underlying biological associations between candidate genes
and all are significantly over-represented (Bonferroni corrected p-
value ≤ 0.05). In some cases, these keywords are expected, given
the phenotype, while other keywords may reveal novel hypotheses
on the underlying etiology associated with the phenotype.
Table 1 GRAIL output
GENE GRAIL p-
value
SELECTED SIMILAR GENES (Rank in
parantheses)
COMT 0.001209104 ARVCF(5), SLC6A4(12), SLC6A3(25)
SLC6A3 0.001209104 SLC6A4(8), COMT(92)
SLC6A4 0.001209104 SLC6A3(16), COMT(97)
For each overlapping candidate gene, GRAIL quantifies the similarity to the
other genes in the set (GRAIL p-value) and ranks genes by similarity. GRAIL
also specifies keywords that characterize the similarity (see text).
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GeneGo’s built in pathways analysis did not reveal any sig-
nificantly over-represented pathways. The 69 genes in this
network were used in hypothesis testing via GAD, and
subsequently were used in the ConceptGen analysis for
differential gene expression.
Hypothesis testing: GAD
The MiMI network that includes the overlapping candi-
dates (Additional file 3, Table S2) shows significant
over-representation of genes associated with both BD
and TUD but the network excluding the overlapping
candidates (Additional file 3, Table S3) is not over-
represented for either phenotype.
The STRING network including the overlapping can-
didates (Additional file 3, Table S4) is significantly asso-
ciated with multiple measures of both BD and TUD.
However, the STRING network that excludes the over-
lapping candidates (Additional file 3, Table S5) is over-
represented only for “smoking behavior” (FDR 0.87%)
and the more general term “mood disorder” (FDR
0.15%), rather than BD.
The original GeneGo network, including the overlap-
ping candidates but excluding nicotine, is over-repre-
sented for genes associated with both BD and TUD
(Additional file 3, Table S6). Excluding the overlapping
candidates, this network is over represented only for the
general term “depressive disorder, major” (Additional
file 3, Table S7). After adding nicotine to this network,
the GeneGo network containing 69 genes is over-repre-
sented for both BD and TUD associated genes, whether
the overlapping candidates are included (Table 5) or
excluded (Table 6). Excluding the overlapping candi-
dates, this network is over-represented for genes asso-
ciated with both “bipolar disorder” (FDR < 0.0001%) and
“smoking behavior” (FDR = 0.0041%).
Hypothesis testing: ConceptGen
ConceptGen finds that genes in the GeneGo network
that includes nicotine are significantly over-represented
(FDR 0.029) in one relevant GEO dataset, GSE10718 [79]
(Table 7). GSE10718 is titled “Time course of NHBE cells
exposed to whole cigarette smoke (full flavor)”. Briefly, in
Figure 4 MiMI network. Overlapping candidates (COMT, SLC6A4, and SLC6A3) are triangular, while their interaction partners are circular.
Table 2 Genes included in the MiMI network
Gene ID Gene Name Gene ID Gene Name Gene ID Gene Name Gene ID Gene Name
26 ABP1 220 ALDH1A3 1644 DDC 6531 SLC6A3
1636 ACE 218 ALDH3A1 9416 DDX23 6532 SLC6A4
124 ADH1A 221 ALDH3B1 10399 GNB2L1 6622 SNCA
125 ADH1B 222 ALDH3B2 9516 LITAF 6804 STX1A
126 ADH1C 314 AOC2 4128 MAOA 7041 TGFB1I1
127 ADH4 8639 AOC3 4129 MAOB 9319 TRIP13
128 ADH5 604 BCL6 4143 MAT1A 22803 XRN2
130 ADH6 811 CALR 4144 MAT2A 4904 YBX1
131 ADH7 1208 CLPS 9463 PICK1
137872 ADHFE1 1312 COMT 5409 PNMT
191 AHCY 1621 DBH 5720 PSME1
For each gene in the MiMI network, Entrez Gene ID and HGNC identifier are listed
McEachin et al. BMC Medical Genetics 2010, 11:14
http://www.biomedcentral.com/1471-2350/11/14
Page 7 of 16
this experiment, normal human bronchial epithelial cells
were exposed to tobacco smoke for 15 minutes, and then
incubated for 2 hours in fresh media. Gene expression
was assayed on the Affymetrix HG-U133 plus 2 microar-
ray, and differential expression was assessed by the Con-
ceptGen expression analysis pipeline.
SNP prioritization via GIN
Based on genes in the GeneGo network that includes
nicotine, for each SNP assayed in both NicSNP and
GAIN, which also shows up in one of our candidate
genes, we summed the GIN prioritization score and the
transformed p-value [-log10(p-value)] from each of the
NicSNP and GAIN studies. Additional file 5, Network_-
cand_SNPs_GIN_NicSNP_GAIN, provides SNPS priori-
tized for validation.
Discussion
We found significant epidemiological evidence for
increased risk of TUD among BD patients (Figure 2), as
well as evidence of increased risk for BD among TUD
patients, consistent with a common underlying etiology
for these two disorders. There is clear evidence in the
Table 3 STRING genes and association scores
Node 1 Node 2 Experimental Score Knowledge Score Textmining Score Combined Score
NACP SLC6A3 0.873 0.9 0.481 0.993
MAOA COMT 0 0.9 0.91 0.991
MAOB COMT 0 0.9 0.848 0.984
DRD2 SLC6A3 0.644 0 0.955 0.983
DRD2 COMT 0 0 0.983 0.983
DRD2 SLC6A4 0 0 0.956 0.956
SLC6A4 COMT 0 0 0.933 0.933
Association between each gene pair is characterized by Experimental, Knowledge, and Textmining scores, as well as the Combined score. Columns of zero scores
have been omitted.
Figure 5 STRING network. The STRING network incorporates the overlapping candidates plus the genes that show the highest combined score
characterizing the association among them.
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literature that both disorders are influenced by both
genetic variation and the environment. Given evidence
of common underlying etiology, as well as evidence of
genetic and environmental influences on both BD and
TUD, we hypothesized a common underlying genetic
etiology, interacting with environmental nicotine expo-
sure, influencing susceptibility to comorbid BD and
TUD. We used multiple bioinformatics resources to test
this hypothesis, including several novel resources.
Meta-analysis
In the meta-analysis, we estimated relative risk for TUD
among BD patients at approximately 2.39 times the risk
for the general population. While we cannot discount
the possibility of heterogeneity, testing suggests that
these seven studies likely are representative of the same
population. Equally, all seven studies show an increased
Relative Risk for TUD among BD patients and, with the
exception of Uock et al., the increased risk is statistically
Figure 6 GeneGo network, including nicotine. The GeneGo network connects the overlapping candidates using the smallest number of
nodes at the highest level of confidence for the edges. Nicotine and the nodes required to connect nicotine to the network have been added.
Overlapping candidate genes (COMT, Dopamine transporter, and SERT) are shown as red, green, and blue circles. Other nodes are coded by the
type of protein coded by the gene (e.g. kinases, transporters, etc.). Edges are labeled for direction of effect, where appropriate, and are green for
activation or red for repression.
Table 4 Genes included in the GeneGo network
Gene ID Gene Name Gene ID Gene Name Gene ID Gene Name Gene ID Gene Name
1636 ACE 1145 CHRNE 5743 PTGS2 112714 TUBA3E
316 AOX1 1146 CHRNG 6233 RPS27A 7277 TUBA4A
624 BDKRB2 1312 COMT 9632 SEC24C 51807 TUBA8
627 BDNF 10987 COPS5 6464 SHC1 203068 TUBB
1134 CHRNA1 1813 DRD2 6571 SLC18A2 81027 TUBB1
57053 CHRNA10 113878 DTX2 6531 SLC6A3 7280 TUBB2A
1135 CHRNA2 1956 EGFR 6532 SLC6A4 347733 TUBB2B
1136 CHRNA3 1958 EGR1 6667 SP1 10383 TUBB2C
1137 CHRNA4 29924 EPN1 6811 STX5 10381 TUBB3
1138 CHRNA5 2060 EPS15 6853 SYN1 10382 TUBB4
8973 CHRNA6 2099 ESR1 7157 TP53 84617 TUBB6
1139 CHRNA7 3320 HSP90AA1 9319 TRIP13 7311 UBA52
55584 CHRNA9 10207 INADL 7846 TUBA1A 7314 UBB
1140 CHRNB1 3725 JUN 10376 TUBA1B 10971 YWHAQ
1141 CHRNB2 84708 LNX1 84790 TUBA1C 7534 YWHAZ
1142 CHRNB3 4842 NOS1 7278 TUBA3C 7704 ZBTB16
1143 CHRNB4 5359 PLSCR1 113457 TUBA3D 51545 ZNF581
1144 CHRND
For each gene in the GeneGo network, including nicotine, Entrez Gene ID and HGNC identifier are listed
McEachin et al. BMC Medical Genetics 2010, 11:14
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Table 5 GAD testing of the GeneGo network, including nicotine and the overlapping candidates
Term Count % PValue Genes Fold
Enrichment
FDR
%
cognitive function 14 20.6 2.8E-18 1137, 6531, 6532, 1138, 1312, 1813, 57053, 1135, 2099, 627, 55584,
1139, 1141, 1142,
36.0 0.000
bipolar disorder 19 27.9 7.2E-15 1137, 6531, 1140, 1143, 8973, 6532, 1138, 1312, 1813, 1136, 57053,
1135, 1636, 627, 55584, 1134, 1139, 1141, 1142,
10.2 0.000
smoking behavior 10 14.7 1.9E-10 6531, 627, 55584, 6532, 4842, 1139, 1312, 1141, 1813, 1142, 21.9 0.000
Parkinson’s disease 12 17.7 2.0E-07 1636, 1137, 6853, 2099, 6531, 627, 6532, 5743, 4842, 1312, 1813,
6571,
7.3 0.000
smoking 6 8.8 1.3E-05 1636, 6531, 7157, 6532, 1141, 1813, 18.1 0.025
methamphetamine abuse 5 7.4 2.1E-05 6531, 627, 6532, 1312, 1813, 27.3 0.042
alcoholism 7 10.3 2.2E-05 1636, 1137, 6531, 627, 6532, 1312, 1813, 11.3 0.042
Alzheimer’s disease 13 19.1 5.3E-05 1137, 7157, 4842, 6532, 1312, 1136, 9632, 1636, 2099, 627, 5743,
1139, 1141,
3.8 0.104
attention deficit hyperactivity
disorder
6 8.8 6.4E-05 1137, 6531, 627, 6532, 1312, 1813, 13.1 0.125
depression 6 8.8 7.2E-05 1636, 6531, 627, 6532, 1312, 1813, 12.8 0.141
depressive disorder, major 6 8.8 1.4E-04 2099, 627, 6532, 4842, 1139, 1813, 11.2 0.275
tardive dyskinesia 5 7.4 1.6E-04 6531, 6532, 4842, 1312, 1813, 16.8 0.318
personality traits 5 7.4 1.6E-04 6531, 627, 6532, 1312, 1813, 16.8 0.318
schizophrenia 13 19.1 3.3E-04 1137, 6531, 7157, 4842, 6532, 1312, 1813, 1636, 627, 5743, 1139,
1141, 6571,
3.1 0.645
mood pain 3 4.4 3.6E-04 627, 6532, 1312, 87.4 0.702
suicide 5 7.4 3.7E-04 1636, 6531, 6532, 4842, 1312, 13.7 0.729
obsessive compulsive disorder 4 5.9 5.3E-04 6531, 627, 6532, 1312, 23.3 1.027
Tourette syndrome 4 5.9 6.4E-04 6531, 6532, 1312, 1813, 21.9 1.253
eating disorders 3 4.4 7.1E-04 627, 6532, 1312, 65.6 1.390
alcoholism attention deficit
hyperactivity disorder
3 4.4 7.1E-04 6532, 1312, 1813, 65.6 1.390
alcohol abuse smoking
behavior
3 4.4 7.1E-04 6531, 6532, 1813, 65.6 1.390
mood disorder 4 5.9 7.7E-04 1636, 627, 6532, 1813, 20.6 1.508
heroin abuse 4 5.9 7.7E-04 6531, 6532, 1312, 1813, 20.6 1.508
anorexia nervosa 4 5.9 9.2E-04 2099, 627, 6532, 1312, 19.4 1.793
schizophrenia; tardive
dyskinesia
3 4.4 1.2E-03 627, 6532, 1312, 52.5 2.290
dystonia, acute parkinsonism
tardive dyskinesia
3 4.4 1.2E-03 6531, 6532, 1813, 52.5 2.290
neuroticism 3 4.4 1.2E-03 627, 6532, 1312, 52.5 2.290
obsessive-compulsive disorder 3 4.4 1.2E-03 627, 6532, 1312, 52.5 2.290
bipolar disorder schizophrenia 4 5.9 1.5E-03 627, 1139, 1312, 6571, 16.7 2.842
premenstrual dysphoric
disorder
3 4.4 1.8E-03 2099, 6532, 1312, 43.7 3.393
kidney failure, chronic
polycystic kidney disease
3 4.4 2.4E-03 624, 1636, 1956, 37.5 4.687
GAD testing, including nicotine and the overlapping candidates, shows significant over-representation for “bipolar disorder” (BD), “smoking behavior” (TUD),
“smoking” (TUD), “alcohol abuse smoking behavior” (TUD) and “bipolar disorder, schizophrenia” (BD).
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significant. We also cannot discount the possibility of
publication bias in this analysis. However, the largest
and most influential studies, Carney and Grant, were
observed in large representative populations and are
unlikely to have been influenced by this bias. MIX per-
formed well on our data and we recommend its use for
similar meta-analyses. These data are consistent with
BD influencing TUD susceptibility, TUD influencing BD
susceptibility, or both BD and TUD being influenced by
some common element(s).
Gene2MeSH
To identify candidate genes for the co-morbidity, we
searched the extensive literature on both BD and TUD
using Gene2MeSH [23]. Gene2MeSH nominates candi-
date genes that are significantly over-represented in lit-
erature annotated for the queried MeSH term.
Gene2MeSH casts a very wide net (all of PubMed) in
searching for gene/MeSH term pairs, performs the
search in seconds, provides a Fisher Exact p-value to
quantify the over-representation of each gene for a
given MeSH term, and sets a threshold of Fisher Exact
p-value ≤ 10-4 to minimize spurious associations. While
this p-value threshold is effective minimizing spurious
associations, in the case of genes that have strong
evidence of association in a relatively small body of lit-
erature, this threshold may exclude valid gene/MeSH
term pairs. We used three queries for TUD ("tobacco
use disorder”, “smoking”, and “nicotine”), though the
query for “smoking” returned all three of the overlap-
ping candidate genes. This suggests that, due to redun-
dancy and ambiguity in MeSH annotation, the user
must be wary in choosing the most appropriate MeSH
terms for Gene2MeSH queries.
Gene2MeSH provides links that allow the user to fol-
low the evidence for a gene/MeSH term pair by
PubMed query. We used these links to validate our can-
didate genes by searching the literature for replicated,
statistically significant (Bonferroni corrected), positive
association with both BD and TUD. This combined
threshold for over-representation and replication
reduces the chance of a false positive association,
though both false positives and false negatives remain
possible. For example, both TPH1 and DRD4 show evi-
dence of association with the comorbidity, but do not
meet the criteria for replication. Future work may reveal
these as true candidate genes for the comorbidity.
Notably, in this analysis and others that rely on pub-
lished data, there is potential for bias in selecting well
studied genes or well studied diseases in developing can-
didate genes. At the same time, analyses that do not
depend on published disease association (e.g. interac-
tions network analysis) may lack relevance to the disease
phenotype of interest. We believe that by combining
these approaches we minimize the effects of bias and
maximize relevance to the phenotype of interest. Gene2-
MeSH performed well on our data and provided candi-
date genes for the analysis and we recommend its use
for similar analyses. Alternately, other approaches to
candidate gene selection (e.g. GWAS or microarray
assay) are useful and could be substituted for Gene2-
MeSH in this analysis.
Common elements
In an effort to understand how our overlapping candi-
dates might interact in predisposing BD and TUD, we
tested them for commonality using two relatively new
algorithms: PDG-ACE [24,25] and GRAIL[26]. PDG-
ACE finds significant commonality among these genes.
Keywords such as “monoamine, psychiatric,
Table 6 GAD testing of the GeneGo network, including nicotine but excluding the overlapping candidates
Term Count % PValue Gene IDs Fold
Enrichment
FDR %
bipolar
disorder
16 24.6 8.5E-12 1137, 1140, 1143, 8973, 1138, 1813, 1136, 57053, 1135, 1636, 627, 55584, 1134,
1139, 1141, 1142
9.34 0.0000
smoking
behavior
7 10.8 2.1E-06 627, 55584, 4842, 1139, 1141, 1813, 1142 16.65 0.0041
GAD testing, including nicotine but excluding the overlapping candidates, shows significant over-representation for “bipolar disorder” (BD) and “smoking
behavior” (TUD).
Table 7 ConceptGen results
Gene Symbol Gene ID p-value Fold Chg
PTGS2 5743 5.0E-11 3.76
EGR1 1958 3.7E-07 2.45
JUN 3725 5.3E-06 1.96
UBB 7314 3.2E-09 1.62
HSP90AA1 3320 4.7E-05 1.23
TUBA4A 7277 5.7E-06 0.78
EPS15 2060 3.6E-05 0.74
TUBB 203068 7.1E-06 0.73
TUBB2C 10383 7.5E-07 0.72
ZNF581 51545 9.1E-05 0.71
TUBB6 84617 4.1E-07 0.70
BDKRB2 624 6.8E-05 0.69
TUBB3 10381 1.1E-07 0.59
13 Genes from the selected GeneGo network are differentially expressed with
tobacco smoke exposure in GSE10718 (gene symbol and Entrez Gene ID, plus
p-value and fold change calculated in the ConceptGen expression analysis
pipeline).
McEachin et al. BMC Medical Genetics 2010, 11:14
http://www.biomedcentral.com/1471-2350/11/14
Page 11 of 16
norepinephrine, prefrontal cortex, illness, trait, and
behavioral” are consistent with the expected roles of
these genes in a psychiatric disorder. Keywords such as
“lithium and suicide” are more specific to BD, while
“methamphetamine and cocaine” are consistent with
substance use disorders, common comorbidities for BD
patients [80]. Keywords “focused and attention” are con-
sistent with both Attention Deficit Disorder [81] and
TUD [82]. The first two categories of keywords serve as
positive controls, showing that PDG-ACE finds expected
relationships among genes that were selected for asso-
ciation with BD and TUD. Note that in earlier testing of
PDG-ACE, we used randomly selected locus pairs as
negative controls to show that it does not find spurious
associations [25]. Reviewing the publications associated
with the keywords that PDG-ACE found significant, we
found that these genes show gender specific effects in
psychiatric and/or substance use disorders. This is con-
sistent with gender differences seen in some studies of
TUD susceptibility, though there are also genetic find-
ings for TUD that have consistent effects in both gen-
ders [40,83-85]. BD susceptibility is often thought to be
independent of gender, so the implication is that follow-
on studies of comorbid BD with TUD might benefit
from analyses that are stratified by gender or explicitly
model gender in association testing. This benefit may
extend to independent BD and TUD phenotypes for
some genes.
GRAIL produced a set of keywords similar to those
produced by PDG-ACE. Keywords “transporter, dopa-
mine, serotonin, uptake, methyltransferase, dopaminer-
gic, and psychiatric”, are consistent with the functions of
these genes in psychiatric disorders, while “subjects,
polymorphisms, patients, risk, genotype, allele, and asso-
ciation” are consistent with the study of the genetic
etiology of complex disease. Keywords “depression, anxi-
ety, schizophrenia, disorder, and attention” are consis-
tent with psychiatric disorders but do not highlight the
comorbidities of BD with substance use. GRAIL could
be improved by providing links to the references used in
the analysis, which would allow the user to follow the
keywords to assess their potential impact in the disease
of interest and, potentially, recognize details such as the
gender-specific effects of these genes in psychiatric and
substance use disorders.
Network hypothesis generation and testing
Hypothesis generation via MiMI, STRING, and GeneGo
proceeded in parallel. MiMI focuses on protein-protein
binding, while STRING and GeneGo also incorporate
functional interactions based on the literature. The
STRING network includes only 7 genes, the MiMI net-
work includes 41 genes, the smaller GeneGo network
includes 52 genes, and the GeneGo network with nico-
tine contains 69 genes. Testing via the Genetic
Association Database reveals the MiMI, STRING, and
smaller GeneGo networks as being generally consistent
with the hypothesis. However, when excluding the over-
lapping candidates none of these networks provides sta-
tistically significant evidence in support of the
hypothesis.
Only the GeneGo network that includes nicotine is
statistically over-represented for genes associated with
both BD and TUD. Interpreting these results, we believe
that the GeneGo network that includes nicotine illus-
trates the importance of environmental nicotine expo-
sure in both BD and TUD susceptibility. Consistent
with this interpretation, the ConceptGen analysis of this
network shows significant over-representation of genes
that are differentially expressed with nicotine exposure.
Notably, this network forms a feedback loop, where
nicotine in the extracellular environment is sensed
inside the cell via binding of nicotine to nicotinic acetyl-
choline receptors, influencing both calcium and neuro-
transmitter signaling. The environmental influence of
nicotine would tend to be amplified over a number of
cycles, potentially leading to a growing imbalance in the
system with continued exposure. As such, we would
expect neurotransmitter and/or calcium signaling to be
increasingly imbalanced, over time, with exposure to
nicotine. This result is also consistent our original
hypothesized interaction between the genetic network
and environmental nicotine exposure in predisposing
both BD and TUD.
In these analyses, we use GAD for hypothesis testing.
While GAD currently has 39,930 records, it remains
under development, and it most certainly includes both
false positive associations and is missing true associa-
tions. Another limitation is that GAD provides only
dichotomous disease association data for each gene,
which does not account for the strength of the evidence
for association, sample size, and methodology. In spite
of these limitations, GAD provides a means for obtain-
ing quantitative measures of disease association for
genetic networks and will become more valuable as
more data are collected and vetted.
We note that the genes identified as being associated
with BD and TUD in our GAD analysis are distinct
from the genes found to be differentially expressed in
the ConceptGen analysis. While this could happen if the
data from GAD or ConceptGen represent false positive
associations, we believe that this is a result of the differ-
ences in hypothesis testing. GAD looks for broad disease
association, which could be caused by a range of dis-
eases-related processes. Since we were focused on envir-
onmental effects on the network, we tested specifically
for differential expression in the ConceptGen analysis.
These are not mutually exclusive tests and may repre-
sent two views of the same or related phenomena.
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While we emphasize that the selected network model
is imperfect, it provides a reasonable model for the com-
plex genetic and environmental influences on BD and
TUD comorbidity. Interestingly, it also models other
phenotypes. For instance, in the GAD analysis (Table 5)
we see “kidney failure, chronic polycystic kidney dis-
ease”, as a phenotype likely influenced by this network.
Kidney failure is clearly a medical phenotype, rather
than a psychiatric phenotype, but this network demon-
strates genetic influences on the comorbidity and on
this medical phenotype [86,87]. Consistent with this
observation, many genes that are expressed in the brain
are expressed in other tissues, so variation that influ-
ences psychiatric disorders may have whole body effects
and influence what are traditionally considered medical
disorders [88-90], thus blurring the boundaries between
psychiatric and medical conditions.
Common elements versus network analysis
In reviewing Table 5, the selected GeneGo network
models multiple elements related to BD and TUD
including: “cognitive function” [91,92], “Parkinson’s dis-
ease” [93,94], multiple forms of substance abuse (alco-
hol, methamphetamine, heroin) [80,95], “attention
deficit hyperactivity disorder” [81,82] (ADHD), and “pre-
menstrual dysphoric disorder” [96,97]. Notably, these
results are consistent with, and expand upon, the results
seen in our PDG-ACE and GRAIL analyses. PDG-ACE
keywords “monoamine, psychiatric, norepinephrine, pre-
frontal cortex, and behavioral”, are consistent with net-
work phenotypes “cognitive function” and “Parkinson’s
disease”. PDG-ACE keywords “methamphetamine, and
cocaine” are consistent with the network’s associations
with substance abuse, while PDG-ACE keywords
“focused, and attention” are consistent with the net-
work’s ADHD association. GRAIL keywords “transpor-
ter, dopamine, serotonin, uptake, methyltransferase, and
dopaminergic” are consistent with the network pheno-
types “cognitive function” and “Parkinson’s disease”,
while GRAIL keyword “attention” is consistent with the
network phenotype ADHD. In addition, the gender spe-
cific effects we saw in following the PDG-ACE results
are consistent with the network phenotype “premenstr-
ual dysphoric disorder”.
Validation testing
Our initial efforts herein have prioritized 14,380 SNPs
for validation based on the integration of evidence from
GIN and GWAS. No specific biological inquiry has been
implemented based on these findings yet, as this work
represents a critical first step in planning further experi-
ments. While this is a relatively large number of target
SNPs, representing a correspondingly large number of
hypothesis tests, the weights provided herein would also
allow researchers to select a subset of these SNPs for
validation. In addition, based on internal GeneGo anno-
tation, this network proposes multiple potential drug
targets for the comorbidity including: EGFR, SLC6A3,
SLC6A4, Tubulin, DRD2, COX2, BDKRB2, ACE1,
COMT, ESR1, and the NACHRs. Any or all of these
genes provide ready targets for drug testing.
Conclusions
The primary limitation of this approach relates to the
validity of the published research in the literature and
databases, which may be plagued by type I and II errors.
In spite of this limitation, this research highlights several
significant points. First, we hypothesized a common
underlying genetic etiology, interacting with environ-
mental nicotine exposure, influencing susceptibility for
both BD and TUD. We find statistically significant evi-
dence in support of this hypothesis in the selected Gen-
eGo network, both via GAD testing for over-
representation of BD and TUD associated genes, and
ConceptGen testing for over-representation of differen-
tially expressed genes. We see gender specific effects of
our overlapping candidate genes, consistent with strati-
fying future BD and TUD analyses by gender or expli-
citly modeling gender in association analysis.
Gene2MeSH provides a useful list of candidate genes
for a particular phenotype (MeSH term), though it is
not an exhaustive list. As seen in the selected GeneGo
network, our overlapping Gene2MeSH candidates
anchor the network and provide a means of identifying
interactions that may be significant in disease, but other
genes in the network are also viable candidates. Our
definitions of psychiatric and medical conditions may be
significantly modified as we progress in identifying
genetic influences on complex diseases. Candidate genes
and drug targets posed by this network may prove valu-
able in improving prognosis for patients with this
comorbidity. In summary, our systems biology approach
provides a model of interacting genetic influences, as
well as gene-by-environment interactions, likely to
impact comorbid DB with TUD.
Additional file 1: Forest Notes. An MS Excel spreadsheet showing the
meta analysis input and output data as well as notes describing
diagnostic criteria for BD and TUD, test and control population, and
derivation of counts for each study.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1471-2350-11-
14-S1.XLS ]
Additional file 2: MOOSE Checklist. An MS Word document that
describes the details of the meta-analysis, consistent with the Reporting
Checklist for Authors, Editors, and Reviewers of Meta-analyses of
Observational Studies - Meta-analysis of Observational Studies in
Epidemiology (MOOSE) criteria.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1471-2350-11-
14-S2.DOCX ]
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Additional file 3: Supplementary Tables. An MS word document that
provides the MIX meta-analysis summary report (Table S1), and 6 tables
of GAD output (Tables S2 through S7).
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1471-2350-11-
14-S3.DOC ]
Additional file 4: Figure S1. A Portable Network Graphics file with the
GeneGo network that connects the overlapping candidates using the
smallest number of nodes at the highest level of confidence for the
edges. Overlapping candidate genes (COMT, Dopamine transporter, and
SERT) are shown as red, green, and blue circles. Other nodes are coded
by the type of protein coded by the gene (e.g. kinases, transporters, etc.).
Edges are labeled for direction of effect, where appropriate, and are
green for activation or red for repression.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1471-2350-11-
14-S4.PNG ]
Additional file 5: Network_cand_SNPs_GIN_NicSNP_GAIN. A comma
separated text file of candidate SNPs prioritized for validation.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1471-2350-11-
14-S5.CSV ]
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